• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[The locoregional treatment of neoplastic ascites with interferon-beta].

作者信息

Cappelli R, Gotti G

机构信息

Istituto di Semeiotica medica e Geriatria, Università, Siena.

出版信息

Recenti Prog Med. 1992 Feb;83(2):82-4.

PMID:1502425
Abstract

Peritoneal effusion recurrence is one of the most important problem in the palliative management of patients with gastrointestinal malignancies and ovarian cancer. Ten patients with recurrent malignant ascites (three with ovarian cancer, two with pancreas cancer, two with gastric adenocarcinoma and one affected by colon cancer, one patient with peritoneal carcinomatosis, one subject with pleural mesothelioma surgically treated that after three years showed a peritoneal metastases and ascites), were treated with intraperitoneal beta interferon. In all patients a Tenckoff's catheter for peritoneal dialysis was introduced and peritoneal effusion extracted and measured. Three millions of beta interferon in saline solution was infused in peritoneal cavity every three days for nine days. Successively twenty millions every three days for nine days. In the 50% of patients a significant reduction of peritoneal effusion was observed. The locoregional therapy with beta interferon is proposed in palliative management of malignant ascites.

摘要

相似文献

1
[The locoregional treatment of neoplastic ascites with interferon-beta].
Recenti Prog Med. 1992 Feb;83(2):82-4.
2
Intracavitary beta-interferon for the management of pleural and/or abdominal effusions in patients with advanced cancer refractory to chemotherapy.
In Vivo. 1991 Nov-Dec;5(6):579-81.
3
[Locoregional ascites therapy with cytostatic drugs and immune modulators in gynecologic neoplasms].[细胞毒性药物和免疫调节剂用于妇科肿瘤的局部区域腹水治疗]
Zentralbl Gynakol. 1991;113(23):1313-22.
4
[Recurrent ascites in peritoneal mesothelioma. Its diagnostic and therapeutic management].[腹膜间皮瘤中的复发性腹水。其诊断与治疗管理]
Rev Esp Enferm Dig. 1995 Mar;87(3):263-6.
5
Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites.腹腔镜下腹腔内热化疗用于缓解恶性难治性腹水
Eur J Surg Oncol. 2006 Aug;32(6):682-5. doi: 10.1016/j.ejso.2006.03.014. Epub 2006 Apr 21.
6
[Cytoreductive surgery and intraperitoneal hyperthermic-antiblastic therapy (HAPP) in peritoneal carcinomatosis].[细胞减灭术及腹腔内热灌注化疗(HAPP)治疗腹膜癌病]
Minerva Chir. 2002 Oct;57(5):597-605.
7
Successful palliation of malignant ascites from peritoneal mesothelioma by laparoscopic intraperitoneal hyperthermic chemotherapy.腹腔镜腹腔内热化疗成功缓解腹膜间皮瘤所致恶性腹水
Surg Laparosc Endosc Percutan Tech. 2008 Aug;18(4):426-8. doi: 10.1097/SLE.0b013e318173a61e.
8
[Chest drainage combined with intracavitary therapy in neoplastic pleural effusion: comparison of three different protocols].[胸腔闭式引流联合腔内治疗恶性胸腔积液:三种不同方案的比较]
G Chir. 1993 Jul;14(6):309-12.
9
Percutaneous placement of peritoneal port-catheter in patients with malignant ascites.恶性腹水患者经皮置入腹膜端口导管
Cardiovasc Intervent Radiol. 2007 Mar-Apr;30(2):232-6. doi: 10.1007/s00270-005-0252-4.
10
Interferon beta adenoviral gene therapy in a patient with ovarian cancer.干扰素β腺病毒基因疗法治疗一名卵巢癌患者。
Nat Clin Pract Oncol. 2006 Nov;3(11):633-9. doi: 10.1038/ncponc0658.

引用本文的文献

1
Tumor stroma engraftment of gene-modified mesenchymal stem cells as anti-tumor therapy against ovarian cancer.基因修饰间充质干细胞肿瘤基质植入作为卵巢癌的抗肿瘤治疗。
Cytotherapy. 2013 Jan;15(1):20-32. doi: 10.1016/j.jcyt.2012.10.003.